Kenzo Muramoto

USPTO Granted Patents = 27 (Patent Applications = 3)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 8.8

ph-index = 6

Forward Citations = 83(Granted Patents)

Location History:

Ibaraki, JP (1993 - 2015)
Tsukuba, JP (2008 - 2017)
Kobe, JP (2019)

Company Filing History:

17 out of 677

Eisai Company, Limited

patents

9 out of 528

Eisai R&d Management Co., Ltd.

4. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2019

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10513561 - Anti-MYL9 antibody (2019-12-24),

2. 9809647 - Neutralizing anti-CCL20 antibodies (2017-11-07),

3. 9453070 - Methods for detecting Th1 cells (2016-09-27),

4. 9200066 - Methods for detecting Th1 cells (2015-12-01),

5. 9175073 - Methods for detecting Th1 cells (2015-11-03),

6. 9133273 - Nucleic acids encoding neutralizing anti-CCL20 antibodies (2015-09-15),

7. 8691814 - Deazapurines and uses thereof (2014-04-08),

8. 8491901 - Neutralizing anti-CCL20 antibodies (2013-07-23),

9. 8329742 - Macrocyclic compounds useful as pharmaceuticals (2012-12-11),

10. 8017344 - Methods for detecting Th1 cells (2011-09-13),

11. 7915306 - Macrocyclic compounds useful as pharmaceuticals (2011-03-29),

12. 7868002 - Deazapurines and uses thereof (2011-01-11),

13. 7799827 - Macrocyclic compounds useful as pharmaceuticals (2010-09-21),

14. 7390490 - Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine (2008-06-24),

15. 7314936 - Deazapurines and uses thereof (2008-01-01),

Title: Kenzo Muramoto: Innovator in Antibody Research

Introduction

Kenzo Muramoto is a prominent inventor based in Tsukuba, Japan, known for his significant contributions to the field of biochemistry, particularly in antibody research. With an impressive portfolio of 27 patents, Muramoto has been at the forefront of innovations that hold potential therapeutic applications.

Latest Patents

Kenzo Muramoto's latest patents highlight his work on novel antibodies with substantial medical implications. One of his key inventions is the **Anti-MYL9 antibody**, which provides a means to inhibit the interaction between Myl9 and CD69 in humans. This invention includes a pharmaceutical composition and the identification of the complementarity determining region (CDR) for a mouse anti-human/mouse Myl9 monoclonal antibody. Furthermore, he developed **neutralizing anti-CCL20 antibodies** that demonstrate binding specificity for the human CC chemokine ligand 20 (CCL20). This patent encompasses humanized, chimeric, and murine antibodies, along with methods for their preparation, targeting inflammatory and autoimmune disorders, as well as cancer.

Career Highlights

Throughout his career, Muramoto has worked with notable companies, including Eisai Company, Limited and Eisai R&D Management Co., Ltd. His innovative work in antibody research has led to advancements that are likely to transform therapeutic strategies in treating various medical conditions.

Collaborations

Muramoto has collaborated with esteemed colleagues, such as Kazuo Okano and Tetsuya Kawahara. These collaborations have fostered an environment of shared knowledge and combined expertise, further enhancing the impact of their research.

Conclusion

Kenzo Muramoto's dedication to innovation in antibody development signifies a remarkable journey of transitioning scientific ideas into practical solutions for real-world health challenges. His substantial contributions continue to shape the future of biochemistry and therapeutic applications, reaffirming his status as a notable inventor in the field.

This text is generated by artificial intelligence and may not be accurate.